Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)

Overview

EPA is developing an Integrated Risk Information System (IRIS) assessment of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and has released the draft assessment for public comment. When final, the assessment will appear on the IRIS database.

Background

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX, or Royal Demolition eXplosive) is a military explosive with limited civilian uses. In the United States, RDX is produced at Army ammunition plants; it is not produced commercially.

An oral reference dose (RfD) and an oral cancer slope factor are currently available on IRIS. A reassessment of the human health effects of RDX, including both cancer effects and effects other than cancer, is being undertaken.

History/Chronology

Date	Description
Aug 2013	EPA released preliminary draft materials for discussion at the December IRIS Bimonthly Public Meeting.
Dec 2013	EPA discussed preliminary draft materials at the December 12-13, 2013 IRIS Bimonthly Public Meeting. Presentations are also available on the meeting web site.
Mar 2016	EPA released the public comment draft for a 60-day review period and announced it will be discussed at the May 10, 2016 IRIS Public Science Meeting. EPA also released the interagency science consultation documents, comments from reviewers, and EPA's response to major comments. [Federal Register Notice: Mar 10, 2016]
Mar 2016	EPA announced a request for nominations of experts to augment the SAB CAAC for the review of the draft RDX assessment. Any related questions should be directed to the SAB. [SAB Federal Register Notice Mar 18, 2016]

Status

Following the public comment period, the assessment will be revised taking into consideration public comments. The assessment will then be released for external peer review.

This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.

• IRIS Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) (Public Comment Draft) (PDF)  (168  pp, 2.3 MB, about PDF)
• Supplemental Information on the IRIS Toxicological Review of RDX (Public Comment Draft) (PDF)  (168  pp, 2.3 MB, about PDF)
• Charge to Reviewers (PDF)  (5  pp, 132.8 KB, about PDF)

If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.

Document Related Link(s)

• IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Preliminary Assessment Materials)
• IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Interagency Science Consultation Draft)
• IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (External Review Draft)

HERO Project

• Primary Literature Search References Sorted By Author (RDX)

Federal Register Notices

• SAB FR Notice: Mar 18, 2016
• FR Notice: Mar 10, 2016

Docket

Comments on the assessment may be submitted and reviewed using the Docket ID EPA-HQ-ORD-2013-0430